NOTE

🌱 created from: Second-line or maintainence therapy for idiopathic thrombocytopenic purpura

fostamatinib

fosta`MATinib

• Fostamatinib is another oral agent recently licensed in the United States.
  • In 2 RCTs:
    • Stable platelet response:
      • Defined as at least 4 of 6 biweekly platelet counts ≥50 × 10³/µL, in absence of rescue, during weeks 14-24.
      • Seen in:
        • 18% of fostamatinib-treated patients
        • 2% of placebo-treated patients.
  • Overall fostamatinib response:
    • At least 1 platelet count ≥50 × 10³/µL in the first 12 weeks.
    • Seen in:
      • 43% of fostamatinib-treated patients.
      • 14% of placebo-treated patients.
    • Time to response: 2 weeks.
  • Study considerations:
    • 24-week study was affected by early entry into open-label phase.
    • 84% of placebo patients and 60% of fostamatinib patients left the study after 12 weeks due to lack of response.
  • Side effects:
    • Diarrhea in 29% of patients.
    • Hypertension in 20% of patients.
    • Nausea in 19% of patients.